Does Retatrutide Work for Everyone?

Retatrutide is an investigational medicine with no UK marketing authorisation, currently studied only within authorised clinical trials for obesity and type 2 diabetes. Whether retatrutide works for everyone is a question the available trial data can only partially answer. The Phase 2 trial published in the New England Journal of Medicine in 2023 showed meaningful weight reductions on average, but individual responses varied across participants. This article summarises what clinical trial findings show about efficacy, variability in response, and the safety profile reported so far, to help readers understand the current state of the evidence.

What is retatrutide and what is its regulatory status in the UK?

Retatrutide holds no UK marketing authorisation and can only be accessed within an authorised clinical trial; it is a triple GLP-1, GIP and glucagon receptor agonist under investigation for obesity and type 2 diabetes.

Retatrutide does not hold a marketing authorisation in the UK or anywhere else, and it can be accessed only within an authorised clinical trial.^[10][11] It is an investigational medicine being studied for the management of obesity and type 2 diabetes. Unlike licensed treatments such as semaglutide (Wegovy, which is licensed for weight management, and Ozempic, which is licensed for type 2 diabetes) or tirzepatide (Mounjaro), retatrutide has not been assessed by the MHRA for routine clinical use, and no authorisation date can be given.^[1][2]

Retatrutide is a triple hormone receptor agonist, meaning it acts simultaneously on three receptors: the glucagon-like peptide-1 (GLP-1) receptor, the glucose-dependent insulinotropic polypeptide (GIP) receptor, and the glucagon receptor.^[10][11] This triple mechanism distinguishes it pharmacologically from currently licensed dual or single agonists, though what this means for individual patients in routine practice cannot be stated outside the context of trial findings.

Because retatrutide is unlicensed, it cannot be advertised, and any product sold online claiming to be retatrutide is not a licensed medicine and may be falsified or unsafe. People interested in licensed weight-management treatments can discuss the options currently available with their GP. Anyone interested in finding out whether any authorised clinical trials involving retatrutide are recruiting in the UK can search the NIHR Be Part of Research portal (bepartofresearch.nihr.ac.uk) or the ISRCTN registry; enrolment and all contact about participation must be through the relevant research team.

What have clinical trials found about how well retatrutide works?

The Phase 2 trial reported a mean weight reduction of approximately 24 per cent at 48 weeks at the highest dose, though individual responses varied and Phase 3 data are not yet complete or regulatory-reviewed.

Clinical trial findings for retatrutide have shown substantial reductions in body weight in trial participants, though these results come from specific study populations under controlled conditions and cannot be generalised to everyone. The Phase 2 trial, published in the New England Journal of Medicine in 2023, enrolled adults with obesity (body mass index of 30 or above, or 27 or above with at least one weight-related comorbidity) but without type 2 diabetes.^[10][11] Participants receiving the highest dose studied (12 mg weekly) achieved a mean body weight reduction of approximately 17.5 per cent at 24 weeks and around 24 per cent at 48 weeks, compared with placebo.

The Phase 3 programme, which includes the TRIUMPH and TRANSCEND trial series, has begun to report results across broader populations, including people with type 2 diabetes, and over longer durations.^[12][13] Initial readouts from these larger trials have been presented at scientific conferences and, in some cases, published in peer-reviewed journals; however, the full dataset across all trial arms and populations is not yet complete, and regulatory review has not taken place. These emerging Phase 3 findings are consistent with meaningful weight reduction and glycaemic benefit in the populations studied, but should be interpreted with caution given the early stage of reporting and the absence of regulatory assessment.

It is important to understand that trial results reflect averages across a defined population. Individual responses varied within the Phase 2 data, and not every participant achieved the mean outcome. Factors such as baseline weight, metabolic profile, adherence to the trial protocol and tolerability of dose escalation all influenced results. These findings are reported here as trial outcomes, not as predictions of what any individual would experience. No conclusions about comparative effectiveness against licensed medicines can be drawn, as no head-to-head trials have been conducted.

What side effects and safety concerns have been reported?

Gastrointestinal effects including nausea, vomiting and diarrhoea were the most common adverse events; heart rate increases and injection site reactions were also reported, and the full safety profile remains under investigation.

The most commonly reported side effects of retatrutide in clinical trials have been gastrointestinal in nature, consistent with the GLP-1 receptor agonist class. These include nausea, vomiting, diarrhoea and constipation, and they occurred most frequently during dose escalation. In the Phase 2 trial, the majority of gastrointestinal events were described as mild to moderate in severity, and most resolved over time.

Pancreatitis is a recognised concern across the GLP-1 receptor agonist class. The UK SmPCs for licensed medicines in this class note that acute pancreatitis has been reported, including post-marketing reports of necrotising pancreatitis and reports with a fatal outcome, though no risk magnitude is established.^[16][17] Participants in retatrutide trials should be aware of symptoms such as persistent, severe abdominal pain and should report these promptly to the trial team.

Heart rate increases were observed in the Phase 2 trial, which is relevant given the glucagon receptor component of retatrutide's mechanism.^[14][15] Injection site reactions were also reported. Because retatrutide is investigational, its full safety profile is not yet established, and longer-term data from the TRIUMPH and TRANSCEND programmes will be important in characterising risks across a wider population.

Anyone participating in an authorised retatrutide trial should report suspected adverse events to the trial team in accordance with the study protocol, and should not stop, restart or alter the study medication without first consulting the trial team. Participants are also advised to carry their trial contact details and to inform any emergency or urgent care clinician that they are enrolled in a clinical trial, so that appropriate advice can be sought from the research team. Suspected side effects can also be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk. For any symptoms that are severe or rapidly worsening, participants should contact NHS 111 for urgent advice or call 999 if the situation is life-threatening.

Does retatrutide work the same way for everyone in the trials?

Retatrutide did not produce identical outcomes for all trial participants; response varied by dose, tolerability, baseline weight and metabolic profile, and full subgroup analyses from Phase 3 trials are not yet published.

Retatrutide did not produce identical outcomes for all participants in the trials conducted so far, and the available evidence suggests that individual response varied meaningfully. In the Phase 2 trial, weight loss outcomes differed across dose groups, with higher doses generally associated with greater reductions, though individual variation within each group was also present.^[10][11] Participants who tolerated the full dose escalation schedule tended to achieve greater weight loss than those who required dose modifications due to side effects.

Baseline characteristics also appeared to influence outcomes. Participants with higher starting body weight, for example, showed different absolute and percentage weight changes compared with those closer to the eligibility threshold. The trial population was defined by specific inclusion and exclusion criteria, including the absence of type 2 diabetes in the Phase 2 obesity study, which means findings may not apply to people with different metabolic profiles.

Initial Phase 3 readouts from the TRIUMPH and TRANSCEND programmes, which enrolled more diverse populations including people with type 2 diabetes, have begun to provide data on outcomes across different subgroups. These early findings suggest variability in response continues to be observed across populations, though the full subgroup analyses from all Phase 3 arms have not yet been published or reviewed by regulators. It is therefore not yet possible to identify with confidence which individuals are most or least likely to respond, and any such conclusions must await complete data and regulatory assessment.

Retatrutide trials have excluded participants who are pregnant, breastfeeding or planning a pregnancy, so no safety or efficacy data are available for these groups.^[10][11] People of childbearing potential enrolled in trials are required to use effective contraception throughout. These exclusions mean that the trial findings cannot be applied to those populations, and this is an important limitation when considering who the evidence does and does not cover.

Frequently Asked Questions